Massachusetts Financial Services CO Travere Therapeutics, Inc. Transaction History

Massachusetts Financial Services CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$23.61 - $30.6 $1.91 Million - $2.48 Million	-81,037 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$24.34 - $31.17 $39,966 - $51,181	-1,642 Reduced 1.99%	81,037 $2.52 Million
Q3 2021 Nov 10, 2021	SELL	$12.98 - $25.03 $221,464 - $427,061	-17,062 Reduced 17.11%	82,679 $2.01 Million
Q2 2021 Aug 13, 2021	BUY	$14.11 - $26.4 $12,078 - $22,598	856 Added 0.87%	99,741 $1.46 Million
Q1 2021 May 13, 2021	SELL	$23.37 - $31.77 $273,873 - $372,312	-11,719 Reduced 10.6%	98,885 $2.47 Million

Q4 2020 Feb 12, 2021	BUY	$19.17 - $27.87 $2.12 Million - $3.08 Million	110,604 New	110,604 $3.02 Million

183

89.5M

66.9K

265K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $560M
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.